Issue : The Pharmaceutical Journal, 21/28 June 2014, Vol 292, No 7815/6
Local practice forum meeting, North East of Scotland Subscription
“Royal Pharmaceutical Society guidance — improving patient outcomes the better use of multi-compartment compliance aids and supporting change.”
Local practice forum meeting, Jersey Subscription
“Meet and greet with local members of the Royal Pharmaceutical Society.” Find out more about what the RPS can do for you and how you can be involved in developing the Jersey LPF.
Premier Inn, Glasgow City Centre George Square, 187 George Street, Glasgow G1 1YU. Meeting 7pm
Local practice forum meeting, Sussex Subscription
“Bridging the gap — transfer of care project, the future,” by Zoe Girdis and Megan Hockly.
Anne Catherine Anderson dies Subscription
Mrs Anderson registered in 1953, became a Fellow in 1992 and left the Society in 2004
A tribute to John Richardson Subscription
In tribute to the late John Richardson (PJ, 7 June 2014, p589), MIALL E JAMES, FRPharmS, writes
The updated summary of product characteristics for Synacten (tetracoside acetate; Alliance) now states that the risks of treatment should be weighed against the benefits if patients have one of the following conditions: ulcerative colitis, diverticulitis, recent intestinal anastomosis, kidney failure, hypertension, predisposition to thromboembolism, osteoporosis, myasthenia gravis.
Lucentis (ranibizumab) is now available in a pre-filled syringe from Novartis. Lucentis vials will continue to be available. Net price, 1 x syringe, £742.17.
Otosporin ear drops Subscription
GlaxoSmithKline has discontinued Otosporin (hydrocortisone, polymyxin B sulphate, neomycin sulphate) ear drops in the UK because of manufacturing complexities. Further information is available on 0800 221 441.
Budesonide gastro-resistant granules (Budenofalk) have been accepted for use within NHS Scotland by the Scottish Medicines Consortium (SMC). The approved indication is the induction of remission in patients with mild to moderate active Crohn’s disease affecting the ileum or ascending colon or both. Defibrotide (Defitelio), for the treatment of severe hepatic veno-occlusive disease, and fluticasone furoate and vilanterol (Relvar Ellipta), for the regular treatment of asthma in adults ...